ENXTBR:UCBPharmaceuticals
UCB (ENXTBR:UCB) Could Be 23% Undervalued After Raised 2026 Guidance
UCB (ENXTBR:UCB) is back in focus after first half 2026 results showed sales of €4.09b and net income of €1.11b, with management also raising full year guidance on the back of BIMZELX momentum.
See our latest analysis for UCB.
Despite the strong first half update, UCB’s 1 month share price return is down 13.57% and the 7 day share price return is down 9.39%. However, the 1 year total shareholder return is 21.12% and the 3 year total shareholder return is very large, which points to longer...